Business

Healthcare Is Becoming Wall Street’s Ultimate Two-Way Trade

By Rhea Lobo
Healthcare Is Becoming Wall Street’s Ultimate Two-Way Trade

Healthcare is finally getting its turn under Wall Street’s spotlight. Investors are rotating toward the sector as tech enthusiasm gets bumpier and earnings visibility becomes more valuable. That combination is drawing both investors looking for shelter and those who still want room for upside.

Finding balance: Healthcare’s rally is running on both blockbusters and breakthroughs. Defensive giants and growthier biotech names are moving higher together, fueled by GLP-1 drugs, progress in cancer treatments, and a pickup in takeover activity. Valuations and dividends add to the appeal, while healthcare earnings are expected to jump 22% next year versus roughly 15% for the S&P 500. Roth’s JC O’Hara called healthcare the “best of both worlds.”

  • The Health Care Select Sector SPDR ETF has climbed 17% in three months, far ahead of the S&P 500’s 2.5% gain.
  • Pfizer yields nearly 6%, while the iShares Biotechnology ETF has surged 27% in three months on takeover hopes.

Crowding Is Becoming The New Risk

Healthcare’s hot streak is starting to create a new risk of its own. Heavy call buying has followed sharp rallies in GE HealthCare Technologies and Medtronic, pushing put-call ratios to levels that one options strategist says now flash sell signals for both stocks. The warning is a useful one for the broader rally, since even a strong sector can leave investors exposed when enthusiasm runs too far ahead of earnings.

  • GE HealthCare climbed more than 12% in three months before put-call ratios flashed crowded optimism.
  • Medtronic soared 26% since late May before options traders triggered another contrarian sell signal.

The rotation broadens: Healthcare is becoming a bigger part of Wall Street’s playbook beyond AI. Around 50 US-listed healthcare funds drew $2.44B in July after nearly $1.5B in June, reversing three straight months of withdrawals. J.P. Morgan analysts called healthcare “a rare combination of durable growth, technology-like profitability, attractive valuation and diversification benefits.” So while the sector has momentum, selectivity matters more with every leg higher.

Go Deeper